Thursday, August 21, 2025
StockstToday.com Logo
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings
No Result
View All Result
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Reiterates Buy Rating on Domo with Revised Price Target

Elaine Mendonca by Elaine Mendonca
March 8, 2024
in Breaking News
0
Finance_Fiscal (3)
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Lake Street analyst Eric Martinuzzi has reiterated his positive outlook on Domo (NASDAQ: DOMO) with a Buy rating. However, he has revised his price target down from $17 to $15. This update comes as of March 8, 2024, reflecting the latest information available.

DOMO Stock Price Plummets on March 8, 2024: What Investors Need to Know

On March 8, 2024, DOMO stock experienced a significant decrease in price, trading near the bottom of its 52-week range and below its 200-day simple moving average. The stock opened at $10.65, which was $0.71 lower than its previous close. Throughout the trading day, the price of DOMO shares dropped by $1.40, resulting in a 12.32% decrease.

This drop in price momentum reflects a bearish sentiment among investors towards DOMO stock on that particular day. The fact that the stock was trading near the bottom of its 52-week range suggests that it may have been facing challenges or experiencing negative news that impacted its performance.

Investors who closely follow technical indicators such as moving averages and price momentum may have been cautious about investing in DOMO on March 8, 2024, given its position below the 200-day simple moving average. This indicator is often used to assess the long-term trend of a stock, and being below it could signal a potential downtrend.

It is important for investors to consider all available information, including technical indicators and fundamental analysis, before making investment decisions. While one day of trading performance does not necessarily indicate the long-term prospects of a stock, it can provide valuable insights into market sentiment and potential trends.

As always, it is recommended to consult with a financial advisor or conduct thorough research before making any investment decisions.

DOMO Inc. Reports Mixed Financial Performance in Q4 2024: Revenue Up, Net Losses Persist

On March 8, 2024, DOMO Inc. (DOMO) reported its financial performance for the past year and the fourth quarter. According to data sourced from CNN Money, DOMO reported a total revenue of $318.99 million for the past year, with a quarterly total revenue of $80.18 million. Compared to the previous year, total revenue increased by 3.35%. However, when compared to the previous quarter, total revenue remained flat.

In terms of net income, DOMO reported a net loss of $75.57 million for the past year, with a quarterly net loss of $18.68 million. Net income increased by 28.41% compared to the previous year but remained unchanged from the previous quarter.

Earnings per share (EPS) is another key metric that investors often look at to assess a company’s financial performance. DOMO reported an EPS of -$2.10 for the past year, with a quarterly EPS of -$0.51. Despite the negative EPS figures, there was a notable improvement of 32.3% compared to the previous year. However, EPS decreased by 12.46% from the previous quarter.

Overall, the performance of DOMO stock on March 8, 2024, reflects a mixed picture of the company’s financial health. While there were some positive indicators such as an increase in total revenue and net income compared to the previous year, the lack of growth in the quarterly figures raises concerns about the company’s ability to sustain its financial performance in the short term. Investors will likely be closely monitoring DOMO’s future earnings reports to assess whether the company can overcome these challenges and deliver sustainable growth in the long run.

Tags: DOMO
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_Commercial

BMO Capital Raises Gap Price Target to 18

Finance_ Investing in stocks

Analyst Increases Price Target for SherwinWilliams Predicts Bright Future Ahead

Bullish Outlook for Smith Wesson Brands Lake Street Analyst Raises Price Target to 16

Recommended

Technology Data analytics Stock Bull Market

Ceridian to Acquire eloomi Revolutionizing People Development

2 years ago

Norwegian Cruise Line Reports Q4 2023 Results and FullYear Outlook

1 year ago
Healthcare-and-IT

Boston Scientific A Decade of Exceptional Growth and Wealth Generation

1 year ago
Technology Data analytics stock Trading (1)

SentinelOne Stock Plummets After Disappointing Fiscal 2025 Guidance

1 year ago

Categories

  • Analyst Ratings
  • Breaking News
  • Business & Industry Trends
  • Cryptocurrency
  • ETF
  • Index
  • Market News
  • Stock Picks
  • Stock Targets
  • Stocks
  • Uncategorized

Topics

AAL AAPL ABNB ADBE ADSK ALB AMD AMZN AVGO BA C CCL CELH COIN COST CRWD CTVA DELL DFS DIS DLR DWAC GM GRFS IBM INTC JPM KSS LLY META MSFT NFLX NIO NVDA NVO ORCL PARA PLTR PLUG QCOM SMCI TGT TSLA UNH VZ
No Result
View All Result

Highlights

JPMorgan Downgrade Sends Custom Truck One Source Shares Tumbling

Chemung Financial Boosts Shareholder Returns with Second Dividend Increase of 2025

Eutelsat’s Strategic Leap into Indonesia’s Connectivity Market

BASF’s Hidden Innovation Unit Emerges as Potential Growth Catalyst

Aker Carbon Capture to Cease Trading Following Shareholder Liquidation Vote

Green Dot Shares Surge on Stellar Quarterly Performance

Trending

Compass Therapeutics Stock
Stocks

Compass Therapeutics: A Biotech Contender Navigates Clinical Progress and Setbacks

by Dieter Jaworski
August 21, 2025
0

The clinical-stage biotech sector is closely watching Compass Therapeutics as it delivers a mix of promising breakthroughs...

Veracyte Stock

Veracyte’s Market Outlook Divides Major Investors

August 21, 2025
Oil-Dri of America Stock

A Niche Performer: Oil-Dri of America’s Impressive Growth Trajectory

August 21, 2025
Custom Truck One Source Stock

JPMorgan Downgrade Sends Custom Truck One Source Shares Tumbling

August 21, 2025
Chemung Stock

Chemung Financial Boosts Shareholder Returns with Second Dividend Increase of 2025

August 21, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Recent News

  • Compass Therapeutics: A Biotech Contender Navigates Clinical Progress and Setbacks August 21, 2025
  • Veracyte’s Market Outlook Divides Major Investors August 21, 2025
  • A Niche Performer: Oil-Dri of America’s Impressive Growth Trajectory August 21, 2025

Categories

  • Analyst Ratings
  • Breaking News
  • Business & Industry Trends
  • Cryptocurrency
  • ETF
  • Index
  • Market News
  • Stock Picks
  • Stock Targets
  • Stocks
  • Uncategorized

© 2024 Stocks Today

No Result
View All Result
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings

© 2023 StocksToday.com